<DOC>
	<DOCNO>NCT01337050</DOCNO>
	<brief_summary>This Asian Phase 1 , multi center , open label , single arm study PF 03446962 dose escalation design define Maximum Tolerated Dose [ MTD ] Recommended Phase 2 Dose [ RP2D ] .</brief_summary>
	<brief_title>Asian Phase I Study Of PF-03446962</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Confirmed diagnosis stomach cancer advanced/metastasis solid tumor refractory intolerant establish therapy adequate blood chemistry , blood count kidney/liver function willing participate study requirement sign inform consent document Chemotherapy , radiotherapy , investigational cancer therapy within 4 week first dose study medication excessive toxicity relate prior therapy pregnant breastfeed patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Advanced/Metastatic solid tumor</keyword>
</DOC>